Heparin cofactor II attenuates vascular remodeling in humans and mice

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1518-1523

  Aihara, Ken Ichi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Heparin cofactor II; Protease activated receptor 1; Thrombin; Vascular remodeling

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEPARIN COFACTOR II; INTERLEUKIN 1BETA; INTERLEUKIN 6; KRUPPEL LIKE FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROTEINASE ACTIVATED RECEPTOR 1; SERINE PROTEINASE INHIBITOR; THROMBIN;

ANGIOGENESIS; ARTERY DISEASE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTERY THROMBOSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DRUG TARGETING; FEMORAL ARTERY; GENE TRANSFER; HUMAN; IN-STENT RESTENOSIS; INHIBITION KINETICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHENOTYPE; PROTEIN DEFICIENCY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; HEPARIN COFACTOR II; HUMANS; MICE; RECEPTOR, PAR-1; THROMBIN; VASCULAR DISEASES;

EID: 77955070480     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0577     Document Type: Review

References (49)

1. Narayanan S. Multifunctional roles of thrombin. Ann Clin Lab Sci 1999; 29: 275-280.
2. Derian CK, Damiano BP, D'Andrea MR, Andrade-Gordon P. Thrombin regulation of cell function through protease-activated receptors: Implications for therapeutic intervention. Biochemistry (Mosc) 2002; 67: 56-64.
3. Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 2003; 10: 211-225.
4. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice defcient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol 1999; 19: 3014-3024.
5. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-78.
6. Major CD, Santulli RJ, Derian CK, Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis: Lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol 2003; 23: 931-939.
7. Tschopl M, Tsakiris DA, Marbet GA, Labs KH, Jager K. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 1997; 17: 3208-3214.
8. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin co-factor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716.
9. Parker KA, Tollefsen DM. The protease specifcity of heparin cofactor II: Inhibition of thrombin generated during coagulation. J Biol Chem 1985; 260: 3501-3505.
10. Rosenberg LC, Choi HU, Tang LH, Johnson TL, Pal S, Webber C, et al. Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages. J Biol Chem 1985; 260: 6304-6313.
11. Tollefsen DM. Heparin cofactor II modulates the response to vascular injury. Arterioscler Thromb Vasc Biol 2007; 27: 454-460.
12. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-1214.
13. Choi HU, Johnson TL, Pal S, Tang LH, Rosenberg L, Neame PJ. Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from bovine articular cartilage and skin isolated by octyl-sepharose chromatography. J Biol Chem 1989; 264: 2876- 2884.
14. Shirk RA, Parthasarathy N, San Antonio JD, Church FC, Wagner WD. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem 2000; 275: 18085-18092.
15. McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fbroblasts and vascular smooth muscle cells. J Biol Chem 1987; 262: 169-175.
16. Rau JC, Deans C, Hoffman MR, Thomas DB, Malcom GT, Zieske AW, et al. Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Exp Mol Pathol 2009; 87: 178-183.
17. Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin co-factor II defciency associated with recurrent thrombosis. Lancet 1985; 2: 414-416.
18. Tran TH, Marbet GA, Duckert F. Association of hereditary heparin co-factor II defciency with thrombosis. Lancet 1985; 2: 413-414.
19. Weisdorf DJ, Edson JR. Recurrent venous thrombosis associated with inherited defciency of heparin cofactor II. Br J Haematol 1991; 77: 125-126.
20. Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM. Heparin cofactor II Oslo. Mutation of Arg-189 to His decreases the affnity for dermatan sulfate. J Biol Chem 1989; 264: 5128-5133.
21. Kanagawa Y, Shigekiyo T, Aihara K, Akaike M, Azuma H, Matsumoto T. Molecular mechanism of type I congenital heparin cofactor (HC) II defciency caused by a missense mutation at reactive P2 site: HC II Tokushima. Thromb Haemost 2001; 85: 101-107.
22. Aihara K, Azuma H, Akaike M, Sata M, Matsumoto T. Heparin cofactor II as a novel vascular protective factor against atherosclerosis. J Atheroscler Thromb 2009; 16: 523-531.
23. Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M, et al. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 2004; 109: 481-486.
24. Huang SS, Huang PH, Chen YH, Sung SH, Chiang KH, Chen JW, et al. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction. Coron Artery Dis 2008; 19: 597-602.
25. Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M, et al. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 2004; 109: 2761-2765.
26. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-128.
27. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.
28. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality: The Whitehall Study. Circulation 1990; 82: 1925-1931.
29. Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: The Framingham Study. Arch Intern Med 2003; 163: 1939-1942.
30. Ouriel K. Peripheral arterial disease. Lancet 2001; 358: 1257-1264.
31. Hsieh CJ, Wang PW. Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circ J 2009; 73: 948-954.
32. Aihara K, Azuma H, Akaike M, Kurobe H, Takamori N, Ikeda Y, et al. Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors. J Atheroscler Thromb 2009; 16: 127-134.
33. Schillinger M, Exner M, Sabeti S, Mlekusch W, Amighi J, Handler S, et al. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Thromb Haemost 2004; 92: 1108-1113.
34. Vanhoutte PM. Endothelial control of vasomotor function: From health to coronary disease. Circ J 2003; 67: 572-575.
35. Vanhoutte PM. Endothelial dysfunction: The frst step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
36. Ando J, Yamamoto K. Vascular mechanobiology: Endothelial cell responses to fuid shear stress. Circ J 2009; 73: 1983-1992.
37. Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, et al. Thrombin suppresses endothelial nitric oxide synthase and up regulates endothelin-converting enzyme-1 expression by distinct pathways: Role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89: 583-590.
38. Nguyen KT, Eskin SG, Patterson C, Runge MS, McIntire LV. Shear stress reduces protease activated receptor-1 expression in human endothelial cells. Ann Biomed Eng 2001; 29: 145-152.
39. Anderson TJ. Prognostic signifcance of brachial fow-mediated vasodilation. Circulation 2007; 115: 2373-2375.
40. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial fow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation 2007; 115: 2390-2397.
41. Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Yu-An Ding P, et al. Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events. Int J Cardiol 2007; 114: 152-158.
42. Borissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res 2009; 82: 392-403.
43. Hayakawa Y, Hirashima Y, Yamamoto H, Hayashi N, Kurimoto M, Kuwayama N, et al. Adenovirus-mediated expression of heparin cofactor II inhibits thrombin-induced cellular responses in fbro-blasts and vascular smooth muscle cells. Thromb Res 2005; 116: 357-363.
44. Schieffer B, Selle T, Hilfker A, Hilfker-Kleiner D, Grote K, Tietge UJ, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 2004; 110: 3493-3500.
45. Solis-Herruzo JA, Rippe RA, Schrum LW, de La Torre P, Garcia I, Jeffrey JJ, et al. Interleukin-6 increases rat metalloproteinase-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fbroblasts. J Biol Chem 1999; 274: 30919-30926.
46. Kamp PB, Ragg H. Rapid changes in the exon/intron structure of a mammalian thrombin inhibitor gene. Gene 1999; 229: 137-144.
47. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-219.
48. Aihara K, Azuma H, Akaike M, Ikeda Y, Sata M, Takamori N, et al. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-defcient mice. J Clin Invest 2007; 117: 1514-1526.
49. Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor II defcient mice. Blood 2007; 110: 4261-4267.